Design and Rationale of the My Heart Counts Cardiovascular Health Study: a Large-Scale, Fully Digital Biobank, and Randomized Trial of Large Language Model-Driven Coaching of Physical Activity - Schmiedmayer, Paul; Johnson, Anders; Schuetz, Narayan; Kollmer, Lukas; Goldschmidt, Paul; Delgado-SanMartin, Juan; Zhang, Kelly W; Mantena, Sriya; Tolas, Alex; Montalvo, Samuel; Ramirez-Posada, Mariana; O’Sullivan, Jack W.; et al. (medRxiv, 2026)
Background Cardiovascular disease remains the leading cause of global morbidity and mortality. The original My Heart Counts smartphone application demonstrated the feasibility of large-scale, fully digital recruitment and trial conduct, but was limited by platform exclusivity and the need for human experts to create text-based behavioral interventions.Methods The next-generation My Heart Counts smartphone application is a prospective, observational cohort study with an embedded randomized crossover trial, evaluating personalized text-based coaching prompts, available in both English and Spanish. All study and trial operations will be conducted via the My Heart Counts smartphone application, re-designed using the open-source Stanford Spezi framework to support iOS, with a planned Android release in 2027. The target enrollment is N=15,000 adults across the United States and United Kingdom. The study establishes a comprehensive digital biobank by synthesizing passive mobile health data (steps, flights climbed, heart rate, sleep, workouts), raw sensor data (e.g., accelerometry), longitudinal clinical surveys, active tasks (6-minute walk test and 12-minute Cooper run test), electrocardiograms (ECG), and electronic health record (EHR) data integrated via HL7 FHIR protocols. The embedded trial evaluates the effect of text-based coaching prompts generated by a large language model (LLM) grounded in the Transtheoretical Model of Change on daily physical activity, as compared to generic prompts.Planned Analysis The primary endpoint of the randomized crossover trial is change in daily step count between LLM-driven and generic text-based intervention arms, analyzed using mixed-effects models. Secondary endpoints include change in mean active minutes and calorie burn over each intervention week. Other analyses include the changes in submaximal (6-minute walk test) and maximal (Cooper 12-minute run test) cardiorespiratory fitness, changes to sensor-derived biomarkers (e.g., sleep quality, resting heart rate, and heart rate variability), and association of sensor-derived biomarkers with EHR-confirmed clinical outcomes.Conclusions By utilizing autonomous, LLM-driven coaching, modular software design, and cross-platform accessibility, our smartphone application-based study will provide a scalable model for inclusive and decentralized preventive care of patients with cardiovascular disease.Trial Status Recruitment commenced in March 2026 and is ongoing.Competing Interest StatementD.S.K. reports grant support from Amgen and the Bristol Myers Squibb Foundation (via the Robert A. Winn Excellence in Clinical Trials Career Development Award). F.R. reports equity from Carta Healthcare and HealthPals, and consulting fees from HealthPals, Novartis, Novo Nordisk, Esperion Therapeutics, Movano Health, Kento Health, Inclusive Health, Edwards, Arrowhead Pharmaceuticals, HeartFlow, and iRhythm outside the submitted work. E.A.A. reports advisory board fees from SequenceBio, Foresite Labs, Pacific Biosciences, and Versant Ventures. E.A.A. has ownership interest in Personalis, Deepcell, Svexa, Candela, Parameter Health, Saturnus Bio, outside the submitted work. E.A.A. is a non-executive director of AstraZeneca and Svexa. E.A.A. receives collaborative research support from Illumina, Pacific Biosciences, Oxford Nanopore, Cache, Cellsonics, outside the submitted work. The remainder of the authors report no potential conflicts of interest. The remainder of the authors declare no competing interests.Funding StatementD.S.K. was supported by the Wu-Tsai Human Performance Alliance as a Clinician-Scientist Fellow, the Stanford Center for Digital Health as a Digital Health Scholar, the Pilot Grant from the Stanford Center for Digital Health, and NIH 1L30HL170306. D.S.K. is presently supported by NIH 9L30DK144879-02, the Robert A. Winn Excellence in Clinical Trials Career Development Award, the American Heart Association (AHA) Career Development Award (AHA 25CDA1436622), and the American Diabetes Association (ADA) Pathway to Stop Diabetes Initiator Award (7-25-INI-11). A.L. is funded by the Imperial BHF Research Excellence Award (4) (RE/24/130023) and British Heart Foundation (RG/F/25/110167). F.R. was funded by grants from the NIH National Heart, Lung, and Blood Institute (R01HL168188; R01HL167974, R01HL169345), the American Heart Association/Harold Amos Medical Faculty Development Program, and the Doris Duke Foundation (Grant #2022051). A.C.K. is supported by NIH grants 5R01AG07149002 and 1R44AG071211, and a seed grant from the Stanford Institute for Human-Centered Artificial Intelligence. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Approval Institutional review boards at Stanford University and Imperial College London have reviewed and granted ethical approval for this prospective cohort study and embedded randomized crossover trial.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript